Citadel Advisors
MBX

Citadel Advisors’s MBX Biosciences MBX Stock Holding History

Citadel Advisors’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$296K Sell
9,900
-7,000
-41% -$238K ﹤0.01% 10503
2025
Q4 		$533K Sell
16,900
-1,700
-9% -$41.2K ﹤0.01% 8874
2025
Q3 		$326K Buy
+18,600
New +$249K ﹤0.01% 10170

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Citadel Advisors's MBX Position: Q1 2026 in Review

Citadel Advisors increased its MBX Biosciences (MBX) stake by 15% in Q1 2026, buying an estimated $4.18M and bringing the position to 932,833 shares worth $27.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1935.

Citadel Advisors first reported a position in MBX in Q3 2024 and has held it in 5 quarters since. 157 funds tracked by Wall St. Rank hold MBX as of Q1 2026.

  • Citadel Advisors held 932,833 shares of MBX Biosciences worth $27.8M as of Q1 2026.
  • Citadel Advisors bought 122,976 MBX Biosciences shares in Q1 2026, an estimated $4.18M.
  • MBX Biosciences made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #1935 holding.
  • Citadel Advisors first reported a position in MBX Biosciences in Q3 2024 and has held it in 5 quarters since.
  • 157 funds tracked by Wall St. Rank held MBX Biosciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.